<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Kinase and Phosphatase Therapeutic Target Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Type</td>
</tr>
<tr>
<td class="label">[LRRK2](/entities/lrrk2-protein)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[GSK3beta](/entities/gsk3-beta)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[CDK5](/proteins/cdk5)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[PP2A](/entities/pp2a)</td>
<td>Phosphatase</td>
</tr>
<tr>
<td class="label">[Calcineurin](/proteins/calcineurin-protein)</td>
<td>Phosphatase</td>
</tr>
</table>
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Kinase and Phosphatase Therapeutic Target Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Type</td>
</tr>
<tr>
<td class="label">[LRRK2](/entities/lrrk2-protein)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[GSK3beta](/entities/gsk3-beta)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[CDK5](/proteins/cdk5)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[PP2A](/entities/pp2a)</td>
<td>Phosphatase</td>
</tr>
<tr>
<td class="label">[Calcineurin](/proteins/calcineurin-protein)</td>
<td>Phosphatase</td>
</tr>
</table>
Protein kinases and phosphatases represent a major class of therapeutic targets in neurodegenerative disease research. These enzymes regulate critical cellular processes including protein phosphorylation, signal transduction, protein turnover, and neuronal survival. Dysregulation of kinase/phosphatase activity has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders. This matrix provides a comprehensive overview of the most clinically advanced kinase and phosphatase targets, their roles in neurodegeneration, the inhibitor development pipeline, and clinical trial status.
The following table summarizes the key kinase and phosphatase targets discussed in this matrix:
LRRK2 is one of the most genetically validated drug targets in Parkinson's disease. Gain-of-function mutations in the LRRK2 gene (PARK8) are the most common cause of familial PD, with the G2019S mutation accounting for 1-5% of familial and 1-2% of sporadic PD cases worldwide [@healy2008]. Pathogenic LRRK2 mutations increase kinase activity by two- to threefold, leading to hyperphosphorylation of Rab GTPases (Rab8A, Rab10, Rab12, Rab29) and disruption of lysosomal and endosomal trafficking [@steger2016].
The most advanced LRRK2 inhibitor is BIIB122 (formerly DNL151, developed by Denali Therapeutics/Biogen), which entered Phase 3 trials as of 2026. The LUMA trial enrolled 650 participants with early-stage PD to evaluate BIIB122 efficacy using MDS-UPDRS as the primary endpoint [@jennings2023]. Earlier candidates include DNL201 (deprioritized in favor of BIIB122) and MK-1468 (Merck), which showed lung toxicity concerns in preclinical studies.
On-target lung effects in type II pneumocytes represent the key safety challenge for LRRK2 inhibitors, requiring careful monitoring in clinical trials [@fuji2015].
GSK3 is a serine/threonine kinase with two isoforms (GSK3α and GSK3β) that plays critical roles in tau hyperphosphorylation, amyloid-β production, neuroinflammation, and neuronal survival. GSK3 is constitutively active in resting neurons and becomes further activated by pathological stimuli in AD and PD [@ballatore2007]. It phosphorylates tau at multiple AD-related sites (Ser396, Ser404, Thr181, Thr231), promoting neurofibrillary tangle formation, and increases β-secretase (BACE1) expression to enhance amyloid-β generation.
Several GSK3 inhibitors have advanced to clinical trials:
Most GSK3 inhibitor programs have been discontinued due to challenges with selectivity and toxicity. No GSK3 inhibitors are currently in Phase 3 trials for neurodegenerative diseases as of 2026.
Achieving adequate brain penetration while maintaining selectivity over off-target effects remains the primary challenge for GSK3 inhibitor development [@hernandez2019].
CDK5 is a proline-directed serine/threonine kinase activated by p35/p39 neuronal-specific regulatory subunits. CDK5 hyperactivation occurs in neurodegenerative conditions through calpain-mediated p35 cleavage to p25, leading to aberrant CDK5 activity that promotes tau hyperphosphorylation, amyloid-β toxicity, and neuronal death [@cruz2005]. CDK5 has also been implicated in PD through regulation of dopaminergic neuron survival and α-synuclein aggregation.
The most advanced CDK5 inhibitor is roscovitine (CYC202, Seliciclib), a pan-CDK inhibitor that has been tested in multiple clinical trials including:
Limited CNS penetration and the lack of highly selective CDK5 inhibitors have hampered clinical development [@cicenas2014].
PP2A is a major serine/threonine phosphatase that regulates tau dephosphorylation. In AD and PD, PP2A activity is reduced, contributing to tau hyperphosphorylation and neurofibrillary tangle formation [@liu2021]. PP2A also dephosphorylates key neuronal substrates including DARPP-32, NMDA receptor subunits, and synaptic proteins. Restoring PP2A activity represents a complementary strategy to kinase inhibition.
Rather than direct PP2A activators, most approaches aim to restore PP2A function indirectly:
Direct PP2A activation is challenging due to the complexity of the PP2A holoenzyme complex; indirect restoration strategies have shown more promise [@van2020].
Calcineurin is a calcium/calmodulin-dependent serine/threonine phosphatase that plays critical roles in neuronal signaling, synaptic plasticity, and immune regulation. In neurodegeneration, calcineurin activity is often dysregulated, contributing to impaired synaptic function and calcium homeostasis. However, calcineurin also plays important roles in neuronal survival pathways through NFAT transcription factor regulation.
No calcineurin inhibitors are currently in clinical trials for neurodegenerative diseases due to the strong immunosuppressive effects of calcineurin inhibition. Research has shifted toward:
The potent immunosuppressive effects of calcineurin inhibitors (such as cyclosporine A and tacrolimus) preclude their use in neurodegenerative disease treatment [@crabtree2002].
Multiple kinase/phosphatase targets may need to be addressed simultaneously for optimal therapeutic effect. For example, combining LRRK2 inhibition with GSK3 inhibition could address both alpha-synuclein and tau pathology in PD. Similarly, PP2A restoration combined with kinase inhibition could provide balanced phosphorylation control.
Each target has specific biomarker strategies:
Emerging approaches include:
Kinase and phosphatase targets represent a rich therapeutic avenue for neurodegenerative diseases. While LRRK2 inhibitors have advanced to Phase 3 for Parkinson's disease, other targets like GSK3, CDK5, and PP2A face significant development challenges. The field continues to evolve with new modalities including protein degradation and gene therapy approaches that may overcome current limitations. Successful disease modification will likely require either combination therapy or highly selective targeting of the most disease-relevant pathways.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: